Profile: Antares Pharma Inc (ATRS.O)
5 May 2015
Antares Pharma, Inc. (Antares), incorporated on April 29, 2005, is a specialty pharmaceutical Company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company developed both subcutaneous and intramuscular injection technology systems which include Vibex disposable pressure-assisted auto injectors, reusable needle-free injectors and disposable multi-use pen injectors. In addition to the development of OTREXUP, the Company has other internal development programs in process that are conducting clinical studies of Vibex QS T, indicated for testosterone replacement therapy and manufacturing development work for Vibex QS M, indicated for an undisclosed central nervous system (CNS) indication. The Company has licensed its reusable needle-free injection device for use with human growth hormone (hGH) to Teva Pharmaceutical Industries, Ltd. (Teva), Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR), with Teva and Ferring being two of its primary customers. Teva markets the Company’s needle-free injection device as the Tjet injector system to administer their 5mg Tev-Tropin brand hGH promoted in the United States and Ferring commercialized its needle-free injection system with their 4mg and 10mg hGH formulations marketed as Zomajet 2 Vision and Zomajet Vision X, respectively, in Europe and Asia. The Company has also licensed both the Vibex disposable auto injector and pen injection devices to Teva for use in certain fields and territories and the Company is engaged in product development activities for Teva utilizing these devices.
The Company’s gel portfolio of products includes Elestrin (estradiol gel), marketed by Meda Pharmaceuticals (Meda) in the United States for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and oxybutynin gel product, Gelnique 3%, for the treatment of overactive bladder (OAB). The Company is engaged in research and development activities related to its Vibex disposable pressure assisted auto injectors and its disposable pen injectors along with Teva. The Company’s pressure assisted auto injectors are designed to deliver drugs by injection from single dose prefilled syringes. The disposable pen injector device is designed to deliver drugs by injection through needles from multi-dose cartridges. The development programs consist of determination of the device design, development of prototype tooling, production of prototype devices for testing and clinical studies, performance of clinical studies and development of commercial tooling and assembly. The Company’s device development programs include: Vibex with Epinephrine, Vibex with Sumatriptan, Disposable pen injector #1 and Disposable pen injector #2. The Company competes with Ypsomed AG, SHL Group AB, OwenMumford Ltd., West Pharmaceuticals, Becton Dickinson, Haselmeir GmbH, Elcam Medical, Vetter Pharma, Bioject Medical Technologies Inc., The Medical House PLC, Actavis, Abbott, Eli Lilly, Auxillium, Inc., Endo Pharmaceuticals, Teva, Mylan, Roxane, Bedford Labs, Sandoz, APP Pharmaceuticals, Hospira, Pfizer, GSK/Astellas, Warner Chilcott and Allergan.
Antares Pharma Inc
SUITE 300, 100 PRINCETON SOUTH
EWING NJ 8628